Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This will be a pilot study to investigate the use of belatacept (BMS) therapy in kidney
transplant patients who have a MAPI score of greater than or equal to 8. The MAPI (Maryland
Aggregate Pathology Index) score is a preimplantation donor scoring system which has five
histopathological parameters that impact long-term kidney outcomes. Many kidney transplant
recipients use calcineurin inhibitors (CNIs) as one of their anti-rejection medi cations.
Kidney function may be affected by anti-rejection medications known as calcineurin inhibitors
(CNIs). Sometimes CNIs can lead to toxicities and eventually loss of the kidney or episodes
of chronic allograft nephropathy (CAN). Avoiding CNI immunosuppression and using belatacept
therapy (BMS) instead, may be associated with improved kidney transplant outcomes.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, College Park